Pancreatic ductal adenocarcinoma (PDAC) features a prominent stromal microenvironment
with remarkable cellular and spatial heterogeneity that meaningfully impacts disease …

Checkpoint inhibitors are being added to standard-of-care chemotherapy in multiple clinical
trials. Success has been reported in non–small and small cell lung carcinomas and …

Dendritic cells (DCs) are a diverse group of specialized antigen-presenting cells with key
roles in the initiation and regulation of innate and adaptive immune responses. As such …

Antigen cross-presentation, wherein dendritic cells (DCs) present exogenous antigen on
major histocompatibility class I (MHC-I) molecules, is considered the primary mechanism by …

Dendritic cells (DCs) play a central role in the regulation of the balance between CD8 T cell
immunity vs. tolerance to tumor antigens. Cross-priming, a process which DCs activate CD8 …

Cancer is a complex disease whose outcome depends largely on the cross-talk between the
tumor and its microenvironment. Here, we review the evolution of the field of tumor …

Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …

Dendritic cells (DC) are professional antigen presenting cells, uniquely able to induce naïve
T cell activation and effector differentiation. They are, likewise, involved in the induction and …

Immune-checkpoint blockade has revolutionized cancer treatment, but some cancers, such
as acute myeloid leukemia (AML), do not respond or develop resistance. A potential mode of …

The heterogeneous nature of tumour microenvironment (TME) underlying diverse treatment
responses remains unclear in nasopharyngeal carcinoma (NPC). Here, we profile 176,447 …